Ohno et al., 2000 - Google Patents
Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki diseaseOhno et al., 2000
- Document ID
- 14732654351505756461
- Author
- Ohno T
- Igarashi H
- Inoue K
- Akazawa K
- Joh-o K
- Hara T
- Publication year
- Publication venue
- European journal of pediatrics
External Links
Snippet
We investigated serum vascular endothelial growth factor (SVEGF) levels in Kawasaki disease and determined whether these levels had any association with the development of coronary artery lesions. We measured SVEGF levels in 66 patients with Kawasaki disease …
- 208000001725 Mucocutaneous Lymph Node Syndrome 0 title abstract description 46
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ohno et al. | Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease | |
Mooradian et al. | Serum levels of tumor necrosis factor and IL-1α and IL-1β in diabetic patients | |
Furukawa et al. | Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease | |
Furukawa et al. | Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumour necrosis factor-α and interleukin 6 in serum | |
Lin et al. | Cytokines predict coronary aneurysm formation in Kawasaki disease patients | |
Oka et al. | Circulating interleukin 6 as a useful marker for predicting postoperative complications | |
Hirao et al. | High levels of circulating lnterleukin-4 and lnterleukin-10 in Kawasaki disease | |
Mahida et al. | High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. | |
Ueno et al. | The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. | |
Chenillot et al. | High sensitivity C-reactive protein: biological variations and reference limits | |
Sato et al. | Cardiovascular biomarkers in acute Kawasaki disease | |
Shulman et al. | Kawasaki disease | |
Keel et al. | Different pattern of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma | |
Ichiyama et al. | NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease | |
PARSONS et al. | Studies on the Role of Tumor Necrosis Factor in Adult Respiratory Distress Syndrome1-3 | |
Ohno et al. | Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease | |
Capelli et al. | Increased macrophage inflammatory protein-1 α and macrophage inflammatory protein-1 β levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis | |
Niu et al. | Early increase in endothelin-1 in tracheal aspirates of preterm infants: correlation with bronchopulmonary dysplasia | |
Virchow Jr et al. | CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma | |
Petricevich et al. | The dynamics of cytokine d nitric oxide secretion in mice injected with Tityus serrulatus scorpion venom | |
Fujieda et al. | Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment | |
Ohnishi et al. | Circulating endothelial glycocalyx components as a predictive marker of coronary artery lesions in Kawasaki disease | |
Kuijpers et al. | Kawasaki disease: a maturational defect in immune responsiveness | |
Rice et al. | Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy | |
Stearman et al. | The use of cytokine and C-reactive protein measurements in cerebrospinal fluid during acute infective meningitis |